Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vincent Medical Holdings Limited (1612.HK)
Hung Hom, HK
Vincent Medical Holdings Limited is an investment holding company engaged in the comprehensive process of designing, manufacturing, marketing, and distributing medical devices. Its operations are bifurcated into two main business models: providing products for other companies (Original Equipment Manufacturing, or OEM) and selling goods under its own proprietary labels (Original Brand Manufacturing). For its OEM clientele, the company specializes in developing respiratory care products, disposable components for imaging contrast media power injectors, and a range of orthopedic and rehabilitation solutions. Its extensive respiratory portfolio encompasses humidification systems, nCPAP interface systems, dedicated respiratory care units, electronic air-oxygen blenders, and anesthesia systems. In the orthopedic and rehabilitation sector, Vincent Medical offers various adjustable braces engineered for post-injury or post-surgical support, protection, and recovery of musculoskeletal areas. The company also pioneers the development of robotic hand training devices. Under its own brand names, including Inspired Medical, Hand of Hope, and Hypnus, Vincent Medical Holdings Limited distributes its offerings across a wide international market. Key regions include the People's Republic of China, the United States, the Netherlands, Australia, and Japan. Established in 1997 and headquartered in Hung Hom, Hong Kong, the company functions as a subsidiary of Vincent Raya International Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.22% | -2.41% | -4.71% | -22.86% | +0.00% | -2.41% | +107.69% | +102.50% | -63.84% | -13.83% | -13.83% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+16.5% ★ Q4'25: +35.5% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+45.5% ★ Q4'25: +71.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+12.5% ★ Q4'25: +14.2% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+14.4% ★ Q4'25: +13.5% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+18.7% ★ Q4'25: +35.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.3% Q4'25: +0.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.14× ★ Q4'25: 0.59× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
467.35M
est: 478.00M (-2.2%)
|
446.30M
est: 444.00M (+0.5%)
|
488.03M
est: 473.00M (+3.2%)
|
502.20M
est: 516.00M (-2.7%)
|
1.16B
est: 1.15B (+0.1%)
|
777.72M
est: 779.00M (-0.2%)
|
629.24M
est: 629.00M (+0.0%)
|
717.97M
est: 748.00M (-4.0%)
|
800.96M
est: 834.00M (-4.0%)
|
932.78M
est: 982.00M (-5.0%)
|
1.17B
1.17B – 1.17B
+18.6% YoY
|
| EBITDA |
77.53M
est: 71.72M (+8.1%)
|
55.71M
est: 66.61M (-16.4%)
|
58.12M
est: 70.97M (-18.1%)
|
49.70M
est: 77.42M (-35.8%)
|
329.25M
est: 103.80M (+217.2%)
|
114.55M
est: 105.70M (+8.4%)
|
29.95M
est: 115.18M (-74.0%)
|
104.43M
est: 121.79M (-14.3%)
|
100.00M
est: 105.37M (-5.1%)
|
155.33M
est: 124.07M (+25.2%)
|
147.19M
147.19M – 147.19M
+18.6% YoY
|
| EBIT |
48.04M
est: 49.75M (-3.5%)
|
19.98M
est: 46.22M (-56.8%)
|
38.94M
est: 49.23M (-20.9%)
|
21.15M
est: 53.71M (-60.6%)
|
292.23M
est: 96.08M (+204.2%)
|
74.49M
est: 97.84M (-23.9%)
|
-11.00M
est: 106.61M (-110.3%)
|
65.78M
est: 112.73M (-41.6%)
|
77.82M
est: 119.04M (-34.6%)
|
134.01M
est: 80.76M (+65.9%)
|
95.80M
95.80M – 95.80M
+18.6% YoY
|
| Net Income |
29.24M
est: 61.02M (-52.1%)
|
13.16M
est: 13.42M (-2.0%)
|
30.94M
est: 39.66M (-22.0%)
|
11.53M
est: 42.71M (-73.0%)
|
216.87M
est: 58.35M (+271.7%)
|
60.70M
est: 59.42M (+2.1%)
|
-17.40M
est: 64.75M (-126.9%)
|
57.28M
est: 68.46M (-16.3%)
|
69.17M
est: 61.28M (+12.9%)
|
104.38M
est: 68.38M (+52.7%)
|
78.05M
78.05M – 78.05M
+14.2% YoY
|
| SGA |
85.60M
est: 85.56M (+0.0%)
|
107.68M
est: 79.48M (+35.5%)
|
116.84M
est: 84.67M (+38.0%)
|
133.96M
est: 92.36M (+45.0%)
|
160.42M
est: 206.64M (-22.4%)
|
125.42M
est: 210.44M (-40.4%)
|
133.65M
est: 229.31M (-41.7%)
|
139.08M
est: 242.46M (-42.6%)
|
151.20M
est: 152.70M (-1.0%)
|
148.61M
est: 179.80M (-17.3%)
|
213.30M
213.30M – 213.30M
+18.6% YoY
|
| EPS |
0.05
est: 0.09 (-44.4%)
|
0.02
est: 0.02 (-1.3%)
|
0.05
est: 0.06 (-21.3%)
|
0.02
est: 0.07 (-72.7%)
|
0.34
est: 0.30 (+14.2%)
|
0.09
est: 0.12 (-19.8%)
|
-0.03
est: -0.03 (+5.0%)
|
0.09
est: 0.08 (+9.5%)
|
0.11
est: 0.10 (+15.8%)
|
0.16
est: 0.11 (+50.9%)
|
0.12
0.12 – 0.12
+14.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ming Fai Koh | Executive VP of Business Development & Executive Director | 2M | male |
| Cheung Tai Choi | Chief Executive Officer & Executive Director | 2M | male |
| Kwok Fu Fu | Executive VP of Technology & Compliance and Executive Director | 2M | male |
| Man Shing Choi | Executive Chairman | 2M | male |
| Wing Fung Yeung | Associate Director of Operations | — | male |
| Wing Kwan Tsui | Head of Corporate Sustainability & Development | — | female |
| Changqing Zhang | Head of Sales & Marketing of Greater China | — | male |
| Yuk Ming Wong | Vice President of Sales & Marketing | — | male |
| Hoi Ming Lai | Chief Financial Officer | — | male |
| Kar Kaan Liang | Associate Director of Operations | — | male |
| Lai Ki Tsui | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1612.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
